Screener
Eterna Therapeutics
ERNAErnexa Therapeutics is a preclinical-stage biotechnology company specializing in the development of synthetic allogeneic induced pluripotent stem cell-derived mesenchymal stem cell (iMSC) therapies.
$2.46M-80.6%
Earnings
Next report
Nov 6, 2026 (In 4 days)EPS estimate-$3.84
Competitors
By market cap
By revenue growth
By net margin
Profile
Ernexa Therapeutics is a preclinical-stage biotechnology company specializing in the development of synthetic allogeneic induced pluripotent stem cell-derived mesenchymal stem cell (iMSC) therapies. The company leverages a proprietary platform to engineer off-the-shelf cell therapies designed to target the tumor microenvironment in cancers and modulate immune responses in autoimmune diseases.
Competitive position
An early-stage innovator in the synthetic iMSC space with a focus on scalable, off-the-shelf allogeneic solutions for solid tumors and autoimmune disorders.
GeographiesUnited States, Japan
Customer segmentsHealthcare providers, Pharmaceutical companies
Business modelR&D focused, IP licensing, Strategic collaborations
SuppliersInduced pluripotent stem cell (iPSC) technology, Contract manufacturing organizations, Academic research institutions, Intellectual property licensors
CustomersClinical trial sites, Strategic pharmaceutical partners, Specialty healthcare providers
CountryUnited States of America
Listed2021
Employees8.0
CEOSanjeev Luther
SectorHealthcare
IndustryBiotechnology
Websiteeternatx.com
FilingsSEC EDGAR
FAQ
- What is Eterna Therapeutics's market cap?
- Eterna Therapeutics (ERNA) has a market capitalization of $2.5M and trades on NASDAQ.
- Who are Eterna Therapeutics's competitors?
- Eterna Therapeutics's key competitors include Calidi Bio, Genelux Corporation, Corcept Therapeutics, and others. These companies compete in similar markets and product categories.
- Who does Eterna Therapeutics partner with?
- Eterna Therapeutics's notable partners include Factor Bioscience Limited, University of Texas MD Anderson Cancer Center, Cellipont Bioservices, and others.
- What subsidiaries does Eterna Therapeutics have?
- Eterna Therapeutics's subsidiaries include Ernexa TX2, Inc..
- Where is Eterna Therapeutics headquartered?
- Eterna Therapeutics is headquartered in United States of America and employs approximately 8 people. It has been publicly traded since 2021.